Hypoxic regulation of angiotensin‐converting enzyme 2 and Mas receptor in human CD34+ cells

CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tes...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 234; no. 11; pp. 20420 - 20431
Main Authors Joshi, Shrinidh, Wollenzien, Hannah, Leclerc, Estelle, Jarajapu, Yagna PR
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.11.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair. Bone marrow–derived progenitor cells are recruited to the areas of hypoxia and stimulate vascular regeneration. Exposure to hypoxia upregulates the expression of angiotensin‐converting enzyme 2 (ACE2) and Mas receptor, and ACE2 shedding in progenitor cells. Activation of Mas by angiotensin‐(1–7), a metabolite of ACE2, stimulates vasoreparative functions in progenitor cells and vascular endothelium.
AbstractList CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair. Bone marrow–derived progenitor cells are recruited to the areas of hypoxia and stimulate vascular regeneration. Exposure to hypoxia upregulates the expression of angiotensin‐converting enzyme 2 (ACE2) and Mas receptor, and ACE2 shedding in progenitor cells. Activation of Mas by angiotensin‐(1–7), a metabolite of ACE2, stimulates vasoreparative functions in progenitor cells and vascular endothelium.
CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2 ) or hypoxia (1% O2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2 ) or hypoxia (1% O2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.
CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin converting enzyme-2 (ACE2)/Angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 + cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 + cells. Cells were isolated from circulating mononuclear cells (MNCs) derived from healthy subjects (n=46) and were exposed to normoxia (20% O 2 ) or hypoxia (1% O 2 ). Luciferase reporter assays were carried out in cells transduced with Lentivirus carrying ACE2- or MasR- or a scramble-3’-UTR gene with firefly luciferase reporter. Expressions or activities of ACE, AT1R, ACE2 and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia increased proliferation and migration of CD34 + cells in basal conditions or in response to VEGF or SDF compared to normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia induced ADAM-17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 + cells, which likely contributes to vascular repair.
CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 + cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 + cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects ( n  = 46) and were exposed to normoxia (20% O 2 ) or hypoxia (1% O 2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34 + cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 + cells, which likely contributes to vascular repair.
CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.
CD34 hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O ) or hypoxia (1% O ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34 cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 cells, which likely contributes to vascular repair.
Author Joshi, Shrinidh
Wollenzien, Hannah
Leclerc, Estelle
Jarajapu, Yagna PR
Author_xml – sequence: 1
  givenname: Shrinidh
  surname: Joshi
  fullname: Joshi, Shrinidh
  organization: North Dakota State University
– sequence: 2
  givenname: Hannah
  surname: Wollenzien
  fullname: Wollenzien, Hannah
  organization: North Dakota State University
– sequence: 3
  givenname: Estelle
  surname: Leclerc
  fullname: Leclerc, Estelle
  organization: North Dakota State University
– sequence: 4
  givenname: Yagna PR
  surname: Jarajapu
  fullname: Jarajapu, Yagna PR
  email: Yagna.Jarajapu@ndsu.edu
  organization: North Dakota State University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30989646$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAUhS1URKeFBS-ALLGhQmn9k3jsDRIaoD8qggUskeU4N1OPEjvYSemw4hF4xj4JbmeKoIKN7-J-5_jce_fQjg8eEHpKySElhB2t7HDIpCj5AzSjRM2LUlRsB81yjxaqKuku2ktpRQhRivNHaJcTJZUoxQx9OVkP4cpZHGE5dWZ0wePQYuOXLozgk_PXP37a4C8hjs4vMfjv6x4wy0SD35uUdRaGMUTsPL6YeuPx4g0vX2ILXZceo4et6RI82dZ99Pnd20-Lk-L8w_Hp4vV5YcuS88LKxlZ125CqVbXMD5lTSaGSjWRCSDFX81ryVgmuqACQLYiqqvM0jcm_E-D76NXGd5jqHhoLfoym00N0vYlrHYzTf3e8u9DLcKmFEIQLkQ1ebA1i-DpBGnXv0s0IxkOYkmaMElZVVPKMPr-HrsIUfR4vU4JTwQgrM_Xsz0S_o9xtPgNHG8DGkFKEVls33u4_B3SdpkTf3Fbn2-rb22bFwT3Fnem_2K37N9fB-v-gPlt83Ch-Aftfs-o
CitedBy_id crossref_primary_10_1016_j_omtm_2020_05_013
crossref_primary_10_1126_scitranslmed_abc0170
crossref_primary_10_1371_journal_pone_0245055
crossref_primary_10_1097_MOH_0000000000000645
crossref_primary_10_1371_journal_pone_0273524
crossref_primary_10_3389_fphys_2022_960308
crossref_primary_10_3390_ijms22157954
crossref_primary_10_3390_v12111213
crossref_primary_10_3390_cells10071752
crossref_primary_10_3389_fmed_2021_670195
crossref_primary_10_1007_s43440_024_00596_3
crossref_primary_10_1042_CS20200480
crossref_primary_10_1042_CS20201133
crossref_primary_10_1007_s12253_020_00810_6
crossref_primary_10_2174_1570159X19666210806163352
crossref_primary_10_3748_wjg_v30_i31_3705
crossref_primary_10_1016_j_meegid_2022_105207
crossref_primary_10_3390_cells12010012
crossref_primary_10_1097_MPA_0000000000001609
crossref_primary_10_1089_ham_2020_0202
crossref_primary_10_3390_cells9071704
crossref_primary_10_1371_journal_pone_0253458
crossref_primary_10_1113_JP280769
crossref_primary_10_1007_s12015_020_10010_z
crossref_primary_10_1016_j_mvr_2021_104232
crossref_primary_10_1016_j_ejcb_2023_151316
crossref_primary_10_1016_j_placenta_2021_12_002
crossref_primary_10_12998_wjcc_v10_i34_12470
crossref_primary_10_3390_ijms222312800
crossref_primary_10_1089_ham_2020_0114
crossref_primary_10_1080_22221751_2021_1932607
crossref_primary_10_1016_j_celrep_2021_109020
crossref_primary_10_3389_fcell_2020_559841
crossref_primary_10_2139_ssrn_3604987
crossref_primary_10_1590_0102_311xen294721
crossref_primary_10_1016_j_jbior_2021_100820
crossref_primary_10_1124_mol_119_117580
crossref_primary_10_1002_path_5555
crossref_primary_10_1126_scisignal_abq1366
crossref_primary_10_3138_ptc_2021_0031
crossref_primary_10_1016_j_jhepr_2023_100936
crossref_primary_10_1159_000520221
crossref_primary_10_1016_j_placenta_2021_01_008
crossref_primary_10_1016_j_ijid_2020_06_080
crossref_primary_10_1038_s41598_021_03710_0
crossref_primary_10_1007_s11357_020_00306_w
crossref_primary_10_1152_ajplung_00259_2020
crossref_primary_10_1152_japplphysiol_00109_2020
crossref_primary_10_13105_wjma_v9_i2_108
crossref_primary_10_1016_j_bcp_2023_115805
crossref_primary_10_1042_CS20200492
crossref_primary_10_1007_s12291_021_00967_0
Cites_doi 10.1167/iovs.10‐70911
10.1093/eurheartj/ehl388
10.1161/HYPERTENSIONAHA.109.140145
10.1159/000493805
10.3389/fphar.2016.00146
10.1016/j.bbrc.2010.12.057
10.1038/srep26131
10.1016/j.ejphar.2016.01.007
10.1152/ajpheart.00854.2014
10.1371/journal.pone.0085958
10.2337/db06‐1254
10.1042/CS20130420
10.1152/ajprenal.00516.2013
10.1161/CIRCRESAHA.109.197723
10.1016/j.bbrc.2007.05.054
10.2337/db16‐1039
10.1210/en.2008‐1274
10.1002/jcb.26440
10.1124/pr.56.4.3
10.1371/journal.ppat.1000520
10.1161/CIRCRESAHA.108.180463
10.1042/CS20130291
10.1152/ajplung.00071.2009
10.1146/annurev.cellbio.15.1.551
10.1634/stemcells.18‐4‐287
10.1073/pnas.1432869100
10.1007/s00280‐002‐0509‐4
10.1161/CIRCRESAHA.109.213140
10.2337/db12‐0808
10.1016/S0028-3908(01)00035-1
10.1016/j.febslet.2007.11.085
10.1371/journal.pone.0037649
10.1371/journal.pone.0062833
10.1007/s11010‐013‐1657‐z
10.1038/onc.2011.522
10.1016/j.molimm.2017.06.029
10.1371/journal.pone.0093965
10.1152/ajplung.90415.2008
10.1210/en.2015‐1556
10.1161/CIRCRESAHA.113.301811
ContentType Journal Article
Copyright 2019 Wiley Periodicals, Inc.
Copyright_xml – notice: 2019 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
5PM
DOI 10.1002/jcp.28643
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

CrossRef
Genetics Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 20431
ExternalDocumentID PMC6660366
30989646
10_1002_jcp_28643
JCP28643
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: National Institute on Aging
  funderid: AG056881
– fundername: American Heart Association
  funderid: 17AIREA33700012
– fundername: American Heart Association-American Stroke Association
  grantid: 13SDG16960025
– fundername: NIGMS NIH HHS
  grantid: P30 GM103332
– fundername: NIA NIH HHS
  grantid: R01 AG056881
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDPE
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ADXHL
AETEA
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c4433-c8dc5bfd05f9b85f907181e58d826686797b83f963916ee8fe655b009daece0e3
IEDL.DBID DR2
ISSN 0021-9541
1097-4652
IngestDate Thu Aug 21 18:11:56 EDT 2025
Fri Jul 11 09:47:17 EDT 2025
Sat Jul 26 00:57:02 EDT 2025
Mon Jul 21 06:02:43 EDT 2025
Tue Jul 01 01:32:03 EDT 2025
Thu Apr 24 22:58:37 EDT 2025
Wed Jan 22 16:41:25 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords ACE2
hypoxia
Mas receptor
CD34+ cells
Language English
License 2019 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4433-c8dc5bfd05f9b85f907181e58d826686797b83f963916ee8fe655b009daece0e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Wollenzien, H. Performed research
Jarajapu, YPR. Designed and supervised the study, and wrote the manuscript.
Joshi, S. Performed and analyzed research
Leclerc, E. Critically analyzed the data and reviewed the manuscript
Author Contributions
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6660366
PMID 30989646
PQID 2263162024
PQPubID 1006363
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6660366
proquest_miscellaneous_2210255183
proquest_journals_2263162024
pubmed_primary_30989646
crossref_citationtrail_10_1002_jcp_28643
crossref_primary_10_1002_jcp_28643
wiley_primary_10_1002_jcp_28643_JCP28643
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2019
PublicationDateYYYYMMDD 2019-11-01
PublicationDate_xml – month: 11
  year: 2019
  text: November 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J Cell Physiol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References e_1_2_9_1_14_1
e_1_2_9_1_37_1
e_1_2_9_1_15_1
e_1_2_9_1_36_1
e_1_2_9_1_12_1
e_1_2_9_1_35_1
e_1_2_9_1_13_1
e_1_2_9_1_34_1
e_1_2_9_1_10_1
e_1_2_9_1_33_1
e_1_2_9_1_11_1
e_1_2_9_1_32_1
e_1_2_9_1_31_1
e_1_2_9_1_30_1
e_1_2_9_1_2_1
e_1_2_9_1_3_1
e_1_2_9_1_4_1
e_1_2_9_1_5_1
e_1_2_9_1_6_1
e_1_2_9_1_29_1
e_1_2_9_1_27_1
e_1_2_9_1_28_1
e_1_2_9_1_25_1
e_1_2_9_1_26_1
e_1_2_9_1_23_1
e_1_2_9_1_24_1
e_1_2_9_1_21_1
e_1_2_9_1_22_1
e_1_2_9_1_42_1
e_1_2_9_1_41_1
e_1_2_9_1_40_1
Mackie A. R. (e_1_2_9_1_20_1) 2011; 38
e_1_2_9_1_7_1
e_1_2_9_1_8_1
e_1_2_9_1_9_1
e_1_2_9_1_18_1
e_1_2_9_1_19_1
e_1_2_9_1_16_1
e_1_2_9_1_39_1
e_1_2_9_1_17_1
e_1_2_9_1_38_1
References_xml – ident: e_1_2_9_1_12_1
  doi: 10.1167/iovs.10‐70911
– ident: e_1_2_9_1_27_1
  doi: 10.1093/eurheartj/ehl388
– ident: e_1_2_9_1_7_1
  doi: 10.1161/HYPERTENSIONAHA.109.140145
– ident: e_1_2_9_1_31_1
  doi: 10.1159/000493805
– ident: e_1_2_9_1_40_1
  doi: 10.3389/fphar.2016.00146
– ident: e_1_2_9_1_32_1
  doi: 10.1016/j.bbrc.2010.12.057
– ident: e_1_2_9_1_33_1
  doi: 10.1038/srep26131
– ident: e_1_2_9_1_16_1
  doi: 10.1016/j.ejphar.2016.01.007
– ident: e_1_2_9_1_29_1
  doi: 10.1152/ajpheart.00854.2014
– ident: e_1_2_9_1_39_1
  doi: 10.1371/journal.pone.0085958
– ident: e_1_2_9_1_2_1
  doi: 10.2337/db06‐1254
– ident: e_1_2_9_1_19_1
  doi: 10.1042/CS20130420
– ident: e_1_2_9_1_25_1
  doi: 10.1152/ajprenal.00516.2013
– ident: e_1_2_9_1_30_1
  doi: 10.1161/CIRCRESAHA.109.197723
– ident: e_1_2_9_1_8_1
  doi: 10.1016/j.bbrc.2007.05.054
– ident: e_1_2_9_1_34_1
  doi: 10.2337/db16‐1039
– volume: 38
  start-page: 474
  issue: 5
  year: 2011
  ident: e_1_2_9_1_20_1
  article-title: CD34‐positive stem cells: In the treatment of heart and vascular disease in human beings
  publication-title: Texas Heart Institute Journal
– ident: e_1_2_9_1_17_1
  doi: 10.1210/en.2008‐1274
– ident: e_1_2_9_1_3_1
  doi: 10.1002/jcb.26440
– ident: e_1_2_9_1_9_1
  doi: 10.1124/pr.56.4.3
– ident: e_1_2_9_1_36_1
  doi: 10.1371/journal.ppat.1000520
– ident: e_1_2_9_1_42_1
  doi: 10.1161/CIRCRESAHA.108.180463
– ident: e_1_2_9_1_6_1
  doi: 10.1042/CS20130291
– ident: e_1_2_9_1_15_1
  doi: 10.1152/ajplung.00071.2009
– ident: e_1_2_9_1_28_1
  doi: 10.1146/annurev.cellbio.15.1.551
– ident: e_1_2_9_1_23_1
  doi: 10.1634/stemcells.18‐4‐287
– ident: e_1_2_9_1_26_1
  doi: 10.1073/pnas.1432869100
– ident: e_1_2_9_1_22_1
  doi: 10.1007/s00280‐002‐0509‐4
– ident: e_1_2_9_1_13_1
  doi: 10.1161/CIRCRESAHA.109.213140
– ident: e_1_2_9_1_11_1
  doi: 10.2337/db12‐0808
– ident: e_1_2_9_1_10_1
  doi: 10.1016/S0028-3908(01)00035-1
– ident: e_1_2_9_1_18_1
  doi: 10.1016/j.febslet.2007.11.085
– ident: e_1_2_9_1_38_1
  doi: 10.1371/journal.pone.0037649
– ident: e_1_2_9_1_5_1
  doi: 10.1371/journal.pone.0062833
– ident: e_1_2_9_1_35_1
  doi: 10.1007/s11010‐013‐1657‐z
– ident: e_1_2_9_1_24_1
  doi: 10.1038/onc.2011.522
– ident: e_1_2_9_1_4_1
  doi: 10.1016/j.molimm.2017.06.029
– ident: e_1_2_9_1_14_1
  doi: 10.1371/journal.pone.0093965
– ident: e_1_2_9_1_41_1
  doi: 10.1152/ajplung.90415.2008
– ident: e_1_2_9_1_21_1
  doi: 10.1210/en.2015‐1556
– ident: e_1_2_9_1_37_1
  doi: 10.1161/CIRCRESAHA.113.301811
SSID ssj0009933
Score 2.5015583
Snippet CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells....
CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells....
CD34 hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells....
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 20420
SubjectTerms ACE2
Adult
Aged
Angiotensin AT1 receptors
Angiotensin-Converting Enzyme 2
Antigens, CD34 - immunology
CD34 antigen
CD34+ cells
Cell migration
Cell proliferation
Cells (biology)
Enzymes
Female
Growth factors
Hematopoietic stem cells
Humans
Hypoxia
Hypoxia - metabolism
Ischemia
Leukocytes (mononuclear)
Male
Mas receptor
Middle Aged
Peptide Fragments - metabolism
Peptidyl-Dipeptidase A - metabolism
Plasmids
Progenitor cells
Proto-Oncogene Mas
Proto-Oncogene Proteins - metabolism
Receptors, G-Protein-Coupled - metabolism
Renin-Angiotensin System - physiology
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - metabolism
Title Hypoxic regulation of angiotensin‐converting enzyme 2 and Mas receptor in human CD34+ cells
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28643
https://www.ncbi.nlm.nih.gov/pubmed/30989646
https://www.proquest.com/docview/2263162024
https://www.proquest.com/docview/2210255183
https://pubmed.ncbi.nlm.nih.gov/PMC6660366
Volume 234
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD6UguCLl9bLaJUoIgWZ7cxkMjvBp7JalkJFxEIflGFya1dtZtkLuH3yJ_gb_SWeJDNT1yqIL8NATkgmOSf5TubkOwDPcMvVMlU6NlILd3QzjN2VkphxUwqdaJMId1H46E0xPs4PT9jJBrzs7sIEfoj-wM1Zhl-vnYHXYr53SRr6SU4HWYkbKq6_LlbLAaJ3l9RRvE0j70MQWJ52rEJJttfXXN-LrgDMq3GSv-JXvwEd3IQPXddD3MnnwXIhBvLiN1bH__y2W3CjBaZkP2jSbdjQdgu29y065ecr8pz4UFF_Br8F10IGy9U2fByvps3XiSSzkNMeZ5k0htT2dNL42Hj749t3H9nu2ApOibYXq3NNMpRQ5KieYz0XV9PMyMQSny-QjF7R_AVxPxTmd-D44PX70ThuMzbEMs8pjWWpJBNGJcxwUeIDAUyZalYq9GIKx-03FCU1aPSISrUujS4YQ8PnqsbWEk3vwqZtrL4PRFCaGJ4LVqCHaJTg2i0eKlE6c5BPRLDbzV0lWzpzl1XjSxWImLMKB7HygxjB0150Gjg8_iS00ylA1ZrxvEJsStMiQxwTwZO-GA3QDUJtdbN0Mqnzy3BpjOBe0Je-FZrwkhd5EcFwTZN6AUfuvV5iJ2ee5BvdSgQXWHPXK8rfO14djt76lwf_LvoQriPw4-FO5Q5sLmZL_QjB1UI89lb0E-8_Inc
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB2VIgQvXFougQIGIVQJZZvESdaWeKm2VEvpVgi1Ul-qaJ3YZYE6q71IbJ_4BL6RL2HGuZSlICFeokgey449Y59xxmcAXuCWq_Ow0L7JtaKjm65PV0r8RBqhdKBNoOii8OAg7R_Fe8fJ8Qq8bu7CVPwQ7YEbWYZbr8nA6UB664I19FM-7kQCd9QrcJUyehNz_s6HC_IoWSeSd0EISRw2vEJBtNVWXd6NLkHMy5GSvyJYtwXt3oKTpvNV5MnnznymOvn5b7yO__t1t-FmjU3ZdqVMd2BF2zVY37bol58t2EvmokXdMfwaXKuSWC7W4aS_GJdfRzmbVGntcaJZadjQno5KFx5vf3z77oLbibDglGl7vjjTLEKJgg2GU6xHoTXlhI0scykDWW-Hx68Y_VOY3oWj3TeHvb5fJ23w8zjm3M9FkSfKFEFipBL4QAwjQp2IAh2ZlOj9ukpwg3aPwFRrYXSaJGj7shhia4Hm92DVllY_AKY4D4yMVZKik2gKJTWtH0VQ6IhQn_Jgs5m8LK8ZzSmxxpes4mKOMhzEzA2iB89b0XFF4_EnoY1GA7LakqcZwlMephFCGQ-etcVogzQIQ6vLOcmE5Jrh6ujB_Uph2lZ4IIVM49SD7pIqtQLE771cYkcfHc83epaIL7DmptOUv3c82-u9dy8P_130KVzvHw72s_23B-8ewQ3EgbK6YrkBq7PJXD9GrDVTT5xJ_QT34yaT
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD7UiuKLl1btaNUoIgWZ7dx3gk9l12WtthSx0IfKsLnV7SWz7AXcPvkT-hv7SzxJZqauVRBfhoGckExyTvKdzMl3AF7jlit5KKSvuGTm6KbtmyslfkpVzmQgVcDMReGd3ay_n2wfpAdL8K6-C-P4IZoDN2MZdr02Bj4SavOKNPSYj1pRjhvqDbiZZAE1eRu6n6-4o2iVR97GIKRJWNMKBdFmU3VxM7qGMK8HSv4KYO0O1LsHh3XfXeDJSWs2ZS1-_hut439-3H24WyFTsuVU6QEsSb0Cq1savfKzOXlDbKyoPYRfgVsuheV8Fb7256Py-5CTsUtqj9NMSkUG-mhY2uB4ffnjwoa2G7qCIyL1-fxMkgglBNkZTLCeCawpx2SoiU0YSDrdOHlLzB-FyUPY773_0un7VcoGnydJHPs8FzxlSgSpoizHByKYPJRpLtCNyQy5X5vlsUKrR1gqZa5klqZo-VQMsLVAxo9gWZdargFhcRwomrA0QxdRCUalWT1EIGRkMB_zYKOeu4JXfOYmrcZp4ZiYowIHsbCD6MGrRnTkSDz-JLReK0BR2fGkQHAah1mEQMaDl00xWqAZhIGW5czIhMYxw7XRg8dOX5pW4oDmNEsyD9oLmtQIGHbvxRI9_GZZvtGvRHSBNTesovy948V2Z8--PPl30Rdwe6_bKz592P34FO4gCKTufuU6LE_HM_kMgdaUPbcG9RNvtiVC
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypoxic+Regulation+of+Angiotensin-Converting+Enzyme+2+and+Mas+Receptor+in+Human+CD34%2B+Cells&rft.jtitle=Journal+of+cellular+physiology&rft.au=Joshi%2C+Shrinidh&rft.au=Wollenzien%2C+Hannah&rft.au=Leclerc%2C+Estelle&rft.au=Jarajapu%2C+Yagna+PR&rft.date=2019-11-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=234&rft.issue=11&rft.spage=20420&rft.epage=20431&rft_id=info:doi/10.1002%2Fjcp.28643&rft_id=info%3Apmid%2F30989646&rft.externalDocID=PMC6660366
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon